Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Aflac is the largest provider of supplemental health insurance in the United States and Japan, with Japan representing approximately 70% of total revenues. The company sells voluntary insurance products (cancer, accident, critical illness, hospital indemnity) primarily through worksite enrollment, generating highly predictable premium income with minimal claims volatility. Aflac's competitive moat stems from its dominant distribution network in Japan (covering 90% of listed companies) and strong brand recognition in both markets.
Aflac collects recurring premiums from policyholders and invests these funds in fixed-income securities, earning spread income between investment returns and claims payouts. The business model benefits from exceptionally low loss ratios (typically 45-55%) on supplemental products since most policyholders never file claims, creating substantial underwriting profit. Pricing power derives from employer-sponsored distribution where employees pay premiums directly through payroll deduction, reducing price sensitivity. The company earns additional spread from investing policyholder funds in Japanese government bonds, U.S. Treasuries, and investment-grade corporate debt, with duration-matched liabilities minimizing interest rate risk on the liability side.
USD/JPY exchange rate movements (70% of earnings from Japan, reported in dollars - yen weakness reduces translated earnings)
Japanese government bond yields and credit spreads (affects $100B+ Japan portfolio returns and hedge costs)
U.S. sales growth and persistency rates in core products (accident, hospital indemnity, critical illness)
Benefit ratio trends in both segments (target 45-50% in U.S., 65-70% in Japan)
Capital deployment actions including dividend increases and share buyback pace ($1.5-2.0B annual authorization)
Secular shift toward high-deductible health plans and Medicare Advantage could reduce demand for supplemental products if comprehensive coverage improves
Japan's declining working-age population (shrinking 0.5-1.0% annually) pressures new sales growth despite aging demographics increasing claims awareness
Regulatory changes in Japan including potential restrictions on cancer insurance sales practices or commission structures
Technology disruption enabling direct-to-consumer digital distribution could disintermediate worksite enrollment model
Increased competition from domestic Japanese insurers (Japan Post, Dai-ichi Life) expanding supplemental product offerings
U.S. market fragmentation with regional competitors and new entrants offering lower-cost digital enrollment platforms
Employer shift toward voluntary benefits platforms (Benefitfocus, bswift) reducing Aflac's direct relationship with employees
Currency translation risk from yen depreciation reducing dollar-reported earnings and book value (70% Japan exposure)
Interest rate risk on hedging costs if U.S.-Japan rate differential widens significantly beyond current forwards
Concentration risk in Japanese government bonds (~40% of total portfolio) exposes company to sovereign credit deterioration
low - Supplemental insurance exhibits counter-cyclical characteristics as economic uncertainty increases demand for income protection products. Premium revenue is highly recurring with 85-90% persistency, insulating top-line from GDP fluctuations. However, severe recessions can pressure sales growth as employers reduce headcount and limit worksite access. Japan's aging demographics provide structural tailwind regardless of economic cycle.
Rising U.S. and Japanese interest rates are highly positive for Aflac's economics. Higher yields increase net investment income on the $140B+ portfolio (60% Japan, 40% U.S.) as securities mature and reinvest at higher rates. The portfolio has 10-12 year duration, so rate increases flow through gradually. Additionally, rising rates reduce the present value of future policy liabilities, improving statutory capital ratios. However, Aflac hedges 50-70% of yen-denominated earnings back to dollars using currency forwards, and higher U.S. rates relative to Japan increase hedging costs, partially offsetting investment income gains.
moderate - Aflac maintains investment-grade fixed-income portfolio (95%+ rated A or better) with minimal equity exposure. Credit spread widening reduces portfolio market value (reported in AOCI) but does not impact statutory earnings unless securities are sold or impaired. The company has minimal direct lending exposure to consumers or corporations beyond bond holdings. Operational credit risk is negligible as policyholders pay premiums upfront through payroll deduction.
dividend - Aflac has increased dividends for 41 consecutive years (Dividend Aristocrat status) with 2.3% current yield, attracting income-focused investors. The stock also appeals to value investors given consistent ROE (13-15%), strong free cash flow generation ($2.7B annually), and modest valuation (11.3x EV/EBITDA). Low earnings volatility and defensive characteristics attract risk-averse institutional investors seeking stable compounders.
low - Beta approximately 0.7-0.8 reflecting defensive insurance business model with predictable cash flows. Stock volatility primarily driven by yen fluctuations rather than fundamental business changes. Implied volatility typically 20-25%, below S&P 500 average.
